Cubist Pharmaceuticals
A U.S. biopharmaceutical company specializing in therapies for serious bacterial infections, acquired by Merck & Co. in 2014.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company built around the research, development, and commercialization of medicines for serious and difficult-to-treat infections. Its work concentrated particularly on hospital-acquired infections and pathogens with significant antimicrobial-resistance concerns, including methicillin-resistant Staphylococcus aureus (MRSA). The company became best known for Cubicin, the trade name for daptomycin, an injectable lipopeptide antibiotic and the first approved member of that anti-infective class. Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, and Barry M. Bloom. The founders also served as directors during the company’s early development. From its base in Lexington, Massachusetts, Cubist developed a business model focused on specialist anti-infective medicines rather than a broad consumer pharmaceutical portfolio. This specialization gave it a distinctive position in an industry where antibacterial research had become commercially difficult and where resistance was increasing the need for new hospital treatments. Cubicin was the company’s central commercial asset. Daptomycin was used for specified serious Gram-positive bacterial infections and became an important treatment option in hospital and infectious-disease settings. Cubist expanded the product’s commercial and legal platform over time, including through patent-related activity and a 2011 settlement with Teva Pharmaceutical Industries concerning Cubicin. The company also sought to diversify beyond its principal product through partnerships, acquisitions, and pipeline development. In 2011, Cubist acquired Adolor Corporation, adding a marketed medicine used in the treatment of opioid-induced constipation and broadening the company’s commercial base beyond anti-infective therapy. That same period included a collaboration with Optimer Pharmaceuticals concerning the co-marketing of fidaxomicin, marketed as Dificid, for Clostridioides difficile infection. Cubist’s development priorities also included Gram-negative bacterial infections, C. difficile infection, and respiratory syncytial virus. In July 2013, it agreed to acquire Trius Therapeutics and Optimer Pharmaceuticals, strengthening its anti-infective pipeline and portfolio. The transactions reflected a strategy of assembling a broader platform in areas of high unmet medical need. A major late-stage achievement was the U.S. approval of tedizolid on June 20, 2014. Tedizolid, marketed as Sivextro after the acquisition, was an oxazolidinone antibiotic developed for certain acute bacterial skin and skin-structure infections. Its approval gave Cubist another important product shortly before the company became part of Merck. Cubist received external recognition for its growth during its independent period. It appeared on Fortune’s 2010 list of fastest-growing companies and was included in the 2010 Deloitte Technology Fast 500. Leadership also changed as the company approached its acquisition: Michael Bonney was succeeded by Robert J. Perez, who was announced as the incoming leader effective January 1, 2015. Merck & Co. agreed in December 2014 to acquire Cubist, with the transaction closing on December 8, 2014 according to the company’s reference history. Cubist subsequently became a wholly owned Merck subsidiary in January 2015. The independent Cubist corporate identity was therefore discontinued, while key products and anti-infective assets were integrated into Merck’s pharmaceutical operations. Cubist is best understood today as a former specialist biopharmaceutical company whose principal legacy is the development and commercialization of daptomycin and the expansion of modern antibiotic portfolios through focused research, licensing, and acquisitions.
History
Cubist Pharmaceuticals was founded in May 1992 by John K. Clarke, Paul R. Schimmel, and Barry M. Bloom. The company was established as a specialist biopharmaceutical enterprise focused on serious infectious diseases, an area requiring scientific expertise in microbiology, infectious disease, and antimicrobial drug development. Its principal operations were based in Lexington, Massachusetts, where most of its workforce was located. The company’s defining product was Cubicin, the brand name for daptomycin. Daptomycin is an injectable lipopeptide antibiotic and was the first approved medicine in that class of anti-infectives. Cubist built its identity and commercial base around the treatment of serious Gram-positive bacterial infections, including infections associated with resistant organisms such as MRSA. Cubicin became particularly important in hospital and specialist-care settings, giving Cubist a strong position in a narrowly defined but medically significant therapeutic area. Cubist’s growth strategy combined internal development with acquisitions and commercial partnerships. In 2011, the company acquired Adolor, bringing in a medicine for opioid-induced constipation and extending its business beyond its flagship antibiotic. Cubist also entered into an arrangement with Optimer Pharmaceuticals involving the co-marketing of fidaxomicin, sold as Dificid, for C. difficile infection. During this period, the company’s pipeline addressed several difficult infectious-disease categories, including Gram-negative bacterial infections, C. difficile infection, and respiratory syncytial virus. Cubicin was also subject to patent litigation. In 2011, Cubist settled a patent dispute with Teva Pharmaceutical Industries concerning the product. The settlement formed part of the legal and commercial management of the company’s most important product franchise. In July 2013, Cubist agreed to acquire Trius Therapeutics and Optimer Pharmaceuticals. These transactions were intended to create a broader anti-infective company with additional late-stage and commercial assets. The acquisitions strengthened Cubist’s capabilities in antibacterial drug development and supported its effort to address infections for which resistance and limited treatment options created substantial clinical need. The company’s independent growth attracted outside recognition. Cubist appeared on Fortune’s 2010 list of fastest-growing companies and was included in the 2010 Deloitte Technology Fast 500. Leadership transitioned during the company’s final independent period: Robert J. Perez was announced as the successor to Michael Bonney as president, taking leadership on January 1, 2015. On June 20, 2014, the U.S. Food and Drug Administration approved tedizolid. The antibiotic was later marketed as Sivextro and provided Cubist with a second important anti-infective product alongside Cubicin. Later in 2014, Merck & Co. agreed to acquire Cubist. The transaction was completed on December 8, 2014, and Cubist became a wholly owned Merck subsidiary in January 2015. The standalone Cubist corporate brand was subsequently absorbed into Merck’s organizational structure. Its principal products and research assets continued under Merck, but Cubist no longer operated as an independent company.
- 2015
Cubist becomes wholly owned by Merck
[1]Cubist became a wholly owned subsidiary of Merck, with Robert J. Perez taking leadership from January 1.
- 2014
Tedizolid receives FDA approval
[1]The FDA approved tedizolid for specified acute bacterial skin and skin-structure infections.
- 2014
Merck acquisition closes
[1]Merck & Co. completed its acquisition of Cubist on December 8, ending Cubist’s independent corporate trajectory.
- 2013
Trius and Optimer transactions announced
[1]Cubist agreed to acquire Trius Therapeutics and Optimer Pharmaceuticals, expanding its anti-infective pipeline and commercial platform.
- 2011
Adolor acquisition
[1]Cubist acquired Adolor, adding a medicine for opioid-induced constipation to its portfolio.
- 2010
Recognition for high growth
[1]Cubist was included in Fortune’s 2010 list of fastest-growing companies and the Deloitte Technology Fast 500.
- 1992
Cubist Pharmaceuticals is founded
[1]John K. Clarke, Paul R. Schimmel, and Barry M. Bloom founded Cubist Pharmaceuticals in May as a biopharmaceutical company focused on serious infectious diseases.
Products and positioning
A specialist anti-infective biopharmaceutical company focused on serious bacterial infections, antimicrobial resistance, and hospital medicine.
Antibiotic
Cubicin
Cubicin was the brand name for daptomycin, an injectable lipopeptide antibiotic developed for specified serious Gram-positive bacterial infections. It was Cubist’s defining product and the commercial foundation of the company. The medicine was associated particularly with hospital treatment and infections involving resistant pathogens such as MRSA. Cubist managed the product’s commercial development and patent position before the asset became part of Merck’s portfolio.
Antibiotic · 2014
Sivextro
Sivextro is the brand name associated with tedizolid, an oxazolidinone antibiotic. The U.S. FDA approved tedizolid on June 20, 2014, for specified acute bacterial skin and skin-structure infections. Its approval gave Cubist a significant additional anti-infective product shortly before the Merck acquisition. The medicine and related development assets were subsequently transferred into Merck’s operations.
Antibiotic for Clostridioides difficile infection
Dificid
Dificid is the brand name for fidaxomicin, an antibiotic used in the treatment of Clostridioides difficile infection. Cubist entered a commercial arrangement with Optimer Pharmaceuticals concerning the co-marketing of the product. The arrangement complemented Cubist’s broader focus on difficult bacterial infections and expanded its commercial activity in a clinically important anti-infective segment.
Gastrointestinal medicine · 2011
Adolor opioid-induced constipation medicine
Through its 2011 acquisition of Adolor, Cubist obtained a medicine used for the treatment of opioid-induced constipation. The asset was outside Cubist’s central antibacterial focus and represented an effort to broaden the company’s commercial portfolio while retaining a specialty-pharmaceutical business model.
Brand decisions
2014
Advance tedizolid into the marketProduct launchBackground
Cubist’s strategy depended on expanding beyond Cubicin with additional treatments for serious bacterial infections.
Action taken
The company obtained FDA approval for tedizolid on June 20, 2014.
Aftermath
Tedizolid became an additional anti-infective product and was later marketed as Sivextro within Merck’s portfolio.
2014
Sell Cubist Pharmaceuticals to MerckM&ABackground
Merck sought to expand its presence in anti-infective medicines, while Cubist had developed a focused portfolio of marketed and pipeline products.
Action taken
Cubist agreed to be acquired by Merck & Co.; the transaction closed on December 8, 2014.
Aftermath
Cubist became a wholly owned Merck subsidiary in January 2015, and its independent corporate identity was discontinued.
Acquisition consideration. (2014)
2013
Pursue Trius Therapeutics and Optimer PharmaceuticalsM&ABackground
Cubist sought to strengthen its position in anti-infective research and add products addressing difficult bacterial infections.
Action taken
Cubist agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals.
Aftermath
The transactions broadened Cubist’s anti-infective pipeline and commercial platform before the company was acquired by Merck.
2011
Acquire Adolor to broaden the portfolioM&ABackground
Cubist was primarily known for anti-infective medicines and sought additional commercial products while maintaining a specialty-biopharmaceutical focus.
Action taken
Cubist acquired Adolor, adding a medicine for opioid-induced constipation.
Aftermath
The transaction expanded Cubist’s product portfolio beyond antibacterial therapy.
Recent events
- 2015
Cubist becomes a wholly owned Merck subsidiary[1]
M&A · Leadership change
Following the acquisition, Cubist operated as a wholly owned subsidiary of Merck, ending its existence as an independent public biopharmaceutical company.
- 2014
FDA approves tedizolid[1]
Product launch · Regulation
The U.S. Food and Drug Administration approved tedizolid, later marketed as Sivextro, for specified acute bacterial skin and skin-structure infections.
- 2014
Merck agrees to acquire Cubist Pharmaceuticals[1]
M&A
Merck & Co. agreed to acquire Cubist, bringing the specialist anti-infective company and its portfolio into Merck’s pharmaceutical operations.
- 2013
Cubist agrees to acquire Trius Therapeutics and Optimer Pharmaceuticals[1]
M&A
Cubist announced agreements to purchase Trius Therapeutics and Optimer Pharmaceuticals, broadening its anti-infective development pipeline and commercial portfolio.
- 2011
Cubist acquires Adolor[1]
M&A
Cubist acquired Adolor Corporation, expanding its portfolio with a medicine for opioid-induced constipation and adding a commercial asset outside its core antibacterial franchise.
- 2011
Cubist settles Cubicin patent litigation with Teva[1]
Lawsuit · Other
Cubist reached a settlement with Teva Pharmaceutical Industries concerning patent litigation related to Cubicin.
- 2011
Cubist enters a co-marketing arrangement for fidaxomicin[1]
Other
Cubist agreed to work with Optimer Pharmaceuticals on the commercialization of fidaxomicin, marketed as Dificid, for Clostridioides difficile infection.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/cubist-pharmaceuticals · Editorial policy · How profiles are compiled